Integrated Oncogene-Tumor Suppressor Signature & Risk Score Modeling Service
Creative Biolabs offers a comprehensive bioinformatics framework established to model the interaction dynamics between oncogenes and tumor suppressors within a research setting. By delivering robust, mathematically defined risk scores derived from transcriptomic data, the service enables the rigorous stratification of study cohorts, the in silico prediction of therapeutic sensitivity, and the validation of putative biomarkers. Access to these publication-quality data packages serves to expedite research and development trajectories and substantiate the statistical rigor of drug discovery endeavors.
Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
The Role of Modeling Oncogenic-Tumor Suppressor
The dynamic equilibrium between oncogenes and tumor suppressor genes (TSGs) constitutes a pivotal determinant in the trajectory of neoplastic progression. While conventional methodologies have predominantly examined these genetic elements in isolation, contemporary investigations within the field of systems biology substantiate the enhanced prognostic utility of integrated molecular signatures. By employing sophisticated regression techniques to model the net expression dynamics of these antagonistic regulatory forces, researchers can elucidate the systemic physiological state of the tumor.
For an in-depth analysis of how our services can be tailored to your specific project needs, request a consultation.
Fig.1 Flow diagram of integrated oncogene-tumor suppressor signature & risk score modeling. 1
What We Can Offer
Customized Risk Model Construction
Tailored development of prognostic signatures specific to your target cancer indication, optimizing the balance between Oncogene and Tumor Suppressor interactions for maximum predictive power.
End-to-End Bioinformatics Solution
A seamless pipeline spanning from raw sequencing data processing and differential expression analysis to sophisticated survival modeling and stratification.
Multi-Omics & Data Integration
Flexible capability to integrate transcriptomics with somatic mutation data (TMB), CNVs, and phenotypic metadata for a holistic, systems-biology level risk assessment.
Therapeutic Efficacy Prediction
Specialized algorithms to predict potential Immunotherapy (ICI) response profiles and perform high-throughput in silico screening for small-molecule drug sensitivity.
How Creative Biolabs Can Assist Your Project
Why Choose Us?
|
Key Advantages
|
Unique Features
|
|
Independent Prognostic Value
|
Our models are rigorously tested to ensure they predict survival independent of standard phenotypic factors like age, gender, and tumor stage.
|
|
Systems Biology Approach
|
We don't just count reads; we analyze the interaction networks between Oncogenes and Tumor Suppressors, capturing the functional state of the tumor sample.
|
|
Proven Accuracy
|
Our signatures consistently achieve high area under the curve (AUC) values in validation datasets.
|
To fully understand the Creative Biolabs advantage, we invite you to get a quote today.
Customer Reviews
-
Prognostic Accuracy
Using Creative Biolabs' integrated oncogene-tumor suppressor signature modeling in our research has significantly improved our ability to identify high-risk breast cancer samples that might benefit from specific pathway targeting. The Nomograms provided were exceptionally clear. - Dr. S**h J***.
-
Drug Repurposing
The drug sensitivity screening included in the service was a game-changer. Using Creative Biolabs' risk score model, we facilitated the identification of a CDK inhibitor that showed specific efficacy in our high-risk group. -M**l R***.
FAQs
Do we need a matched normal tissue control for every tumor sample?
Ideally, yes, to accurately define differential expression. However, if matched controls are unavailable, Creative Biolabs can utilize high-quality normal tissue data from the GTEx database to serve as a robust reference baseline for your analysis.
How does your risk score compare to tumor mutation burden (TMB)?
TMB measures genomic instability, while our risk score measures transcriptomic functional state. They are complementary; in fact, combining our Risk Score with TMB often yields the highest predictive accuracy for immunotherapy response research.
Related Services
Tumor Metabolic Microenvironment Analysis
Comprehensive assessment of TME hypoxia, pH, and nutrient competition using single-cell metabolomics to uncover metabolic vulnerabilities driving immune suppression and tumor progression.
Learn More →
Single-cell Tools based Lineage Tracing Service
Map tumor evolutionary history and clonal architecture at cellular resolution to identify origin cells, metastatic clones, and therapy-resistant lineages.
Learn More →
How to Contact Us
Creative Biolabs bridges the gap between complex genomic data and research utility. By providing robust, validated prognostic models, we empower you to make data-driven decisions that accelerate drug development and improve scientific understanding. To facilitate the conversion of experimental data into predictive assets, please contact our scientific team for further information and to discuss specific project requirements.
Reference
-
Wang, Qian et al. "Development and Validation of a Three-Gene Prognostic Signature Based on Tumor Microenvironment for Gastric Cancer." Frontiers in genetics vol. 12 801240. 1 Feb. 2022. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fgene.2021.801240
For Research Use Only | Not For Clinical Use
Download our brochure